SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition

Area of Science:

• Hematology
• Molecular Biology
• Genetics

Background:

• Mutations in spliceosomal proteins are common in myelodysplastic syndromes (MDS).
• The precise role of these mutations in MDS pathogenesis remains unclear.
• Understanding these mutations is crucial for deciphering MDS development.

Purpose of the Study:

• To investigate the role of SRSF2 mutations in MDS pathogenesis.
• To elucidate the functional consequences of SRSF2 mutations on hematopoietic differentiation.
• To identify the molecular mechanisms linking SRSF2 mutations to MDS.

Main Methods:

• In vivo studies of hematopoietic differentiation in the presence of SRSF2 mutations.
• Analysis of SRSF2's RNA binding activity and its impact on splicing.
• Investigation of downstream effects of altered splicing on key hematopoietic regulators, including EZH2.

Main Results:

• SRSF2 mutations directly impair hematopoietic differentiation in vivo.
• The impairment is not due to a loss of SRSF2 function.
• SRSF2 mutations alter sequence-specific RNA binding, leading to mis-splicing of critical hematopoietic regulators.
• SRSF2 mutation-dependent splicing of EZH2 triggers nonsense-mediated decay, resulting in impaired differentiation.

Conclusions:

• SRSF2 mutations are mechanistically linked to impaired hematopoiesis in MDS.
• Altered RNA binding and subsequent mis-splicing of key regulators drive MDS pathogenesis.
• These findings provide a direct link between spliceosomal protein mutations and MDS.